• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓增殖性肿瘤中的血栓形成:对其影响骨髓纤维化、死亡率和实体瘤的观点。

Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.

机构信息

FROM, Fondazione per la Ricerca Ospedale di Bergamo ETS, Bergamo, Italy.

Dipartimento di Scienze Mediche e Chirurgiche, Materno-Infantili e dell'Adulto, Università di Modena-Reggio Emilia, Modena, Italy.

出版信息

Blood Cancer J. 2024 Oct 25;14(1):188. doi: 10.1038/s41408-024-01169-6.

DOI:10.1038/s41408-024-01169-6
PMID:39455571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11512069/
Abstract

This viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs) to assess the impact of thrombosis on mortality, disease progression, and second cancers (SC). Despite advances, the current incidence of arterial and venous thrombosis remains a challenge. These events appear to signal a more aggressive disease course, as evidenced by their association with myelofibrosis progression and mortality using multistate models and time-dependent multivariable analysis. Inflammatory biomarkers, such as the neutrophil-to-lymphocyte ratio (NLR), are associated with the aggressiveness of polycythemia vera (PV) and essential thrombocythemia (ET), linking thrombosis to SC risk. This suggests a common inflammatory pathway likely influencing cardiovascular disease and cancer incidence. Notably, this is observed more frequently in younger patients, likely due to prolonged exposure to MPN and environmental inflammatory triggers. These data underscore the need for new studies to validate these associations, delineate the sequence of events, and identify therapeutic targets to mitigate thrombotic events and potentially improve overall patient outcomes in MPN.

摘要

这一观点总结了对骨髓增生性肿瘤(MPN)大型患者个人数据库分析的结果,以评估血栓形成对死亡率、疾病进展和第二癌症(SC)的影响。尽管取得了进展,但目前动脉和静脉血栓形成的发生率仍然是一个挑战。这些事件似乎表明疾病进展更为激进,这一点可通过多状态模型和时间依赖性多变量分析,证明其与骨髓纤维化进展和死亡率相关。炎症生物标志物,如中性粒细胞与淋巴细胞比值(NLR),与原发性骨髓纤维化(PV)和特发性血小板增多症(ET)的侵袭性相关,将血栓形成与 SC 风险联系起来。这表明可能存在一条共同的炎症途径,影响心血管疾病和癌症的发病率。值得注意的是,这种情况在年轻患者中更为常见,可能是由于长期暴露于 MPN 和环境炎症触发因素所致。这些数据强调需要进行新的研究来验证这些关联,阐明事件的顺序,并确定治疗靶点,以减轻血栓形成事件,并有可能改善 MPN 患者的整体预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea69/11512069/62fa0eae1132/41408_2024_1169_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea69/11512069/b7ea8b795113/41408_2024_1169_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea69/11512069/7c5ad777a0ca/41408_2024_1169_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea69/11512069/62fa0eae1132/41408_2024_1169_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea69/11512069/b7ea8b795113/41408_2024_1169_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea69/11512069/7c5ad777a0ca/41408_2024_1169_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ea69/11512069/62fa0eae1132/41408_2024_1169_Fig3_HTML.jpg

相似文献

1
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors.骨髓增殖性肿瘤中的血栓形成:对其影响骨髓纤维化、死亡率和实体瘤的观点。
Blood Cancer J. 2024 Oct 25;14(1):188. doi: 10.1038/s41408-024-01169-6.
2
Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.费城染色体阴性骨髓增殖性肿瘤中的血栓形成
Cancer Treat Res. 2019;179:159-178. doi: 10.1007/978-3-030-20315-3_11.
3
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].[JAK2V617F突变在慢性骨髓增殖性肿瘤患者中的意义]
Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226.
4
Thrombosis among 1537 patients with JAK2 -mutated myeloproliferative neoplasms: Risk factors and development of a predictive model.1537 例 JAK2 突变骨髓增殖性肿瘤患者的血栓形成:危险因素和预测模型的建立。
Cancer Med. 2020 Mar;9(6):2096-2105. doi: 10.1002/cam4.2886. Epub 2020 Jan 28.
5
Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis.高中性粒细胞比率对骨髓增殖性肿瘤血栓形成的预测意义:JSH-MPN-R18 亚分析。
Ann Hematol. 2024 Sep;103(9):3535-3541. doi: 10.1007/s00277-024-05898-3. Epub 2024 Jul 22.
6
Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.骨髓纤维化中的内脏静脉血栓形成——疾病表型的一个被低估的特征。
Int J Mol Sci. 2023 Oct 29;24(21):15717. doi: 10.3390/ijms242115717.
7
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.脑静脉血栓形成与骨髓增殖性肿瘤:来自两个大型数据库的结果
Thromb Res. 2014 Jul;134(1):41-3. doi: 10.1016/j.thromres.2014.03.040. Epub 2014 Mar 29.
8
Thrombocytosis and Thrombosis: Is There Really a Correlation?血小板增多症与血栓形成:真的有关联吗?
Curr Hematol Malig Rep. 2020 Aug;15(4):261-267. doi: 10.1007/s11899-020-00588-z.
9
A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.一项关于费城阴性骨髓增殖性肿瘤诊断时血栓形成和出血发生率的系统评价和荟萃分析。
BMC Cancer. 2019 Feb 28;19(1):184. doi: 10.1186/s12885-019-5387-9.
10
Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.2016 年世界卫生组织定义的费城阴性骨髓增殖性肿瘤中的血栓和出血事件。
Korean J Intern Med. 2021 Sep;36(5):1190-1203. doi: 10.3904/kjim.2020.634. Epub 2021 Jul 22.

引用本文的文献

1
Consequences and impacts of PEG-IFNα2a shortage: first lessons from a MPN French center.聚乙二醇干扰素α2a短缺的后果与影响:来自法国一家骨髓增殖性肿瘤中心的初步经验教训
Ann Hematol. 2025 Jul 17. doi: 10.1007/s00277-025-06510-y.
2
Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis.骨髓纤维化患者静脉和动脉血栓形成事件的分子预测指标
Ann Hematol. 2025 Apr 27. doi: 10.1007/s00277-025-06361-7.

本文引用的文献

1
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.阿司匹林与安慰剂作为乳腺癌辅助治疗的比较:ALLIANCE A011502 随机试验。
JAMA. 2024 May 28;331(20):1714-1721. doi: 10.1001/jama.2024.4840.
2
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study.年龄分层分析揭示动脉血栓形成是骨髓增殖性肿瘤中与性别相关的第二原发癌症的预测因素:一项病例对照研究。
Blood Cancer J. 2024 Apr 22;14(1):68. doi: 10.1038/s41408-024-01052-4.
3
Cardiovascular disease and cancer: shared risk factors and mechanisms.
心血管疾病和癌症:共同的风险因素和机制。
Nat Rev Cardiol. 2024 Sep;21(9):617-631. doi: 10.1038/s41569-024-01017-x. Epub 2024 Apr 10.
4
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation.接受芦可替尼治疗的骨髓纤维化患者中性粒细胞与淋巴细胞比值可预测预后和停药率。
Eur J Haematol. 2024 Jun;112(6):938-943. doi: 10.1111/ejh.14188. Epub 2024 Feb 9.
5
Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms-a Danish longitudinal study.中性粒细胞与淋巴细胞比值与有无骨髓增生性肿瘤患者的全因死亡率:一项丹麦纵向研究。
Blood Cancer J. 2024 Feb 9;14(1):28. doi: 10.1038/s41408-024-00994-z.
6
Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients.来自两项涉及2000名患者的纵向研究的原发性血小板增多症预测模型。
Blood Cancer J. 2024 Jan 23;14(1):17. doi: 10.1038/s41408-024-00987-y.
7
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience.一千例原发性血小板增多症患者:佛罗伦萨-CRIMM 研究经验。
Blood Cancer J. 2024 Jan 18;14(1):10. doi: 10.1038/s41408-023-00968-7.
8
Association between elevated white blood cell counts and thrombotic events in polycythemia vera: analysis from REVEAL.真性红细胞增多症中白细胞计数升高与血栓事件的相关性:REVEAL 分析。
Blood. 2024 Apr 18;143(16):1646-1655. doi: 10.1182/blood.2023020232.
9
CHIP-JAK2V617F, chronic inflammation, abnormal megakaryocyte morphology, organ failure, and multimorbidities.CHIP-JAK2V617F、慢性炎症、异常巨核细胞形态、器官衰竭和多种疾病。
Blood Adv. 2024 Feb 13;8(3):681-682. doi: 10.1182/bloodadvances.2023012190.
10
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients.血栓形成对真性红细胞增多症患者死亡和疾病进展概率的影响:1545 例患者的多状态转移分析。
Blood Cancer J. 2023 Dec 15;13(1):187. doi: 10.1038/s41408-023-00960-1.